Leukemia inhibitory factor is a novel biomarker to predict lymph node and distant metastasis in pancreatic cancer
Leukemia inhibitory factor is a novel biomarker to predict lymph node and distant metastasis in pancreatic cancer
复制标题
白血病抑制因子是预测胰腺癌淋巴结和远处转移的新型生物标志物
DOI：
10.1002/ijc.33291
复制
发表时间：
2020-10-05
影响因子：
6.4
通讯作者：
Ren, Li
中科院分区：
文献类型：
--
作者：
Jiang, Wenna;Bai, Weiwei;Ren, Li
胰腺癌的生存率较低，大多数患者在诊断时已出现淋巴结转移和远处转移。尽管人们努力提高总生存期（OS）和无复发生存期（RFS），但胰腺癌的预后仍然很差，这凸显了识别新的生物标志物来预测胰腺癌患者转移的重要性。白血病抑制因子（LIF）在多种癌症中过度表达，并参与包括胰腺癌在内的多种恶性肿瘤的发生。然而，LIF 作为预测胰腺癌转移的生物标志物的作用仍不清楚。在本研究中，单变量和多变量 Cox 回归分析确定胰腺肿瘤组织中的 LIF 表达是与较差 OS 和 RFS 相关的独立危险因素。 LIF 过表达与不良临床病理特征相关，例如淋巴结转移和病理分期 (pTNM) 分期。胰腺癌患者的血清 LIF 水平高于健康对照者。受试者工作特征曲线下面积表明，血清 LIF 比其他生物标志物（CA199 和 CEA）更能有效预测淋巴结和远处转移。
Pancreatic cancer has a low survival rate, and most patients have lymph node metastasis and distant metastasis at the time of diagnosis. Despite efforts to improve overall survival (OS) and recurrence free survival (RFS), the prognosis of pancreatic cancer remains poor, underscoring the importance of identifying new biomarkers to predict metastasis in patients with pancreatic cancer. Leukemia inhibitory factor (LIF) is overexpressed in many types of cancer and is involved in the development of various malignancies including pancreatic cancer. However, the role of LIF as a biomarker to predict metastasis in pancreatic cancer remains unclear. In this study, univariate and multivariate Cox regression analyses identified LIF expression in pancreatic tumor tissues as an independent risk factor related to worse OS and RFS. LIF overexpression was related to poor clinicopathological features such as lymph node metastasis and Pathological stage (pTNM) stage. Serum LIF levels were higher in pancreatic cancer patients than in healthy controls. The area under the receiver operating characteristic curve indicated that serum LIF is more effective than other biomarkers (CA199 and CEA) for predicting lymph node and distant metastasis.